BRIEF published on 06/18/2024 at 12:35, 2 years 4 months ago Crossject: Information relating to the total number of voting rights and shares making up the share capital Share Capital Voting Rights AMF Crossject Specialized Pharmacy
BRIEF published on 06/13/2024 at 09:41, 2 years 4 months ago Crossject: Information on the number of voting rights and shares Share Capital Voting Rights Actions 2024 Crossject
BRIEF published on 06/12/2024 at 07:35, 2 years 4 months ago Crossject Appoints Dan Chiche, MD as North America Chief Medical Officer Crossject ZEPIZURE® Dan Chiche Medical Director
PRESS RELEASE published on 06/12/2024 at 07:30, 2 years 4 months ago Crossject appoints Dan Chiche, MD as Chief Medical Officer North America Crossject appoints Dan Chiche, MD as Chief Medical Officer North America, strengthening leadership team and expanding presence in U.S. Supports ZEPIZURE® regulatory milestones targeting in 2025 North America Chief Medical Officer Crossject ZEPIZURE Dan Chiche
BRIEF published on 06/04/2024 at 19:35, 2 years 4 months ago Crossject Announces Successful Closing of €8 Million Rights Offering FDA Approval Rights Offering Crossject ZEPIZURE® Epilepsy Treatment
PRESS RELEASE published on 06/04/2024 at 19:30, 2 years 4 months ago Crossject announces highly successful closing of its €8 million rights offering Crossject successfully closes €8 million rights offering, securing funding for ZEPIZURE® development and FDA approval. Gemmes Venture remains a key supporter FDA Approval Rights Offering Crossject ZEPIZURE® Gemmes Venture
BRIEF published on 05/30/2024 at 10:35, 2 years 5 months ago Crossject: Publication of Clinical Data on ZEPIZURE® Crossject ZEPIZURE® Neurology And Therapy Midazolam Needle-free Injection
PRESS RELEASE published on 05/30/2024 at 10:30, 2 years 5 months ago Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy Crossject announces publication of clinical data on ZEPIZURE in Neurology and Therapy, highlighting bioequivalence versus Dormicum, early onset, and low variability Clinical Data Crossject Neurology And Therapy ZEPIZURE Needle-free Auto-injector
Published on 11/02/2026 at 23:15, 6 hours 42 minutes ago ATHA Energy Announces Issuance of Common Shares in Satisfaction of US$25 Million Convertible Debenture Interest Payment Obligations
Published on 11/02/2026 at 22:30, 7 hours 27 minutes ago Sparton Files Morrison Mine N-I 43-101 Technical Report
Published on 11/02/2026 at 17:00, 12 hours 57 minutes ago PPX Mining Initiates Operating Permit Process for Igor Processing Plant
Published on 11/02/2026 at 17:00, 12 hours 57 minutes ago QNX Launches Global Developer Hackathon with $50,000 in Prizes to Accelerate Innovation in Mission-Critical Systems
Published on 11/03/2026 at 03:30, 2 hours 27 minutes ago ADTRAN Holdings, Inc. reports third quarter 2026 financial results
Published on 11/03/2026 at 03:25, 2 hours 31 minutes ago How President Xi Jinping Has Charted the Course for Boosting China's Strength in Finance: Pursuing a Path of Financial Development with Chinese Characteristics
Published on 11/03/2026 at 02:55, 3 hours 1 minute ago WESCAN GOLDFIELDS ANNOUNCES ENGAGEMENT OF RED CLOUD SECURITIES FOR LIQUIDITY SERVICES
Published on 11/02/2026 at 23:11, 6 hours 45 minutes ago EQS-Adhoc: HUGO BOSS AG: HUGO BOSS UPDATES ITS FULL YEAR 2026 OUTLOOK
Published on 11/02/2026 at 22:05, 7 hours 52 minutes ago Abivax to Participate in Upcoming Fall Investor Conferences
Published on 11/02/2026 at 18:30, 11 hours 27 minutes ago Disclosure of transactions in own shares from October 26 to October 30, 2026
Published on 11/02/2026 at 18:17, 11 hours 39 minutes ago Reporting on share buyback transactions carried out between October 28 and October 29, 2026
Published on 11/02/2026 at 18:00, 11 hours 57 minutes ago Covivio - Information on total number of voting rights and share capital
Published on 11/02/2026 at 17:59, 11 hours 57 minutes ago Saint-Gobain completes the divestment of its Dahl specialist distribution business in Sweden, Norway and Denmark
